Skip to Main Content
Table 3

Hazard ratio (95% CI) for the sulfonylurea monotherapy comparisons for mortality in the entire cohort and the subgroup with documented CAD

Hazard ratio (95% CI)P value
Entire cohort contrast   
    Glyburide vs. glimepiride 1.00 (0.89–1.14) 0.952 
    Glipizide vs. glyburide 1.04 (0.94–1.15) 0.430 
    Glipizide vs. glimepiride 1.05 (0.92–1.19) 0.499 
CAD subgroup contrast   
    Glyburide vs. glimepiride 1.36 (0.96–1.91) 0.081 
    Glipizide vs. glyburide 1.03 (0.80–1.31) 0.838 
    Glipizide vs. glimepiride 1.39 (0.99–1.96) 0.059 
Hazard ratio (95% CI)P value
Entire cohort contrast   
    Glyburide vs. glimepiride 1.00 (0.89–1.14) 0.952 
    Glipizide vs. glyburide 1.04 (0.94–1.15) 0.430 
    Glipizide vs. glimepiride 1.05 (0.92–1.19) 0.499 
CAD subgroup contrast   
    Glyburide vs. glimepiride 1.36 (0.96–1.91) 0.081 
    Glipizide vs. glyburide 1.03 (0.80–1.31) 0.838 
    Glipizide vs. glimepiride 1.39 (0.99–1.96) 0.059 

Mortality model adjusted for baseline covariates: age, sex, race (Caucasian vs. non-Caucasian), Modification of Diet in Renal Disease estimated glomerular filtration rate, A1C, BMI, systolic blood pressure, diastolic blood pressure, HDL cholesterol, LDL cholesterol, triglycerides, smoking status, ACE or angiotensin receptor blocker therapy, aspirin therapy, clopidogrel therapy, cholesterol-lowering medication, new diabetes, CAD, congestive heart failure, and median household income.

Close Modal

or Create an Account

Close Modal
Close Modal